Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage

Immunome Research

Volumn 6, Issue 1, 2010, Pages

  Kotturi, Maya F ^a   Botten, Jason ^b   Maybeno, Matt ^a   Sidney, John ^a   Glenn, Jean ^a   Bui, Huynh Hoa ^a   Oseroff, Carla ^a   Crotty, Shane ^a   Peters, Bjoern ^a   Grey, Howard ^a   Altmann, Daniel M ^c   Buchmeier, Michael J ^d   Sette, Alessandro ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; EPITOPE; GLYCOPROTEIN; HLA ANTIGEN CLASS 2; NUCLEOCAPSID PROTEIN; PEPTIDE VACCINE; RNA DIRECTED RNA POLYMERASE; ZINC FINGER PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARENAVIRUS; ARENAVIRUS INFECTION; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; GUANARITO VIRUS; INFECTION PREVENTION; JUNIN VIRUS; LASSA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACHUPO ARENAVIRUS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SABIA VIRUS; TRANSGENIC MOUSE; VACCINIA VIRUS; VIRUS RECOMBINANT; WHITEWATER ARROYO VIRUS;

EID: 77953154971     PISSN: None     EISSN: 17457580     Source Type: Journal    
DOI: 10.1186/1745-7580-6-4     Document Type: Article

References (58)

1. Arenaviridae: the viruses and their replication. MJ Buchmeier JC de la Torre CJ Peters, Fields Virology Lippincott Williams & Wilkins, a Wolters Klumer Business, Knipe DM, Howley PM, 2007 2 1791 1828
2. Lymphocytic choriomeningitis virus: reemerging central nervous system pathogen. LL Barton NJ Hyndman, Pediatrics 2000 105 35 10.1542/peds.105.3.e35 10699137
3. Lymphocytic choriomeningitis virus: emerging fetal teratogen. LL Barton MB Mets CL Beauchamp, Am J Obstet Gynecol 2002 187 1715 1716 10.1067/mob.2002.126297 12501090
4. Congenital lymphocytic choriomeningitis virus infection: spectrum of disease. DJ Bonthius R Wright B Tseng L Barton E Marco B Karacay PD Larsen, Ann Neurol 2007 62 347 355 10.1002/ana.21161 17557350 (Pubitemid 350105949)
5. Arenaviruses. JP Gonzalez S Emonet X de Lamballerie R Charrel, Curr Top Microbiol Immunol 2007 315 253 288
6. Clinical and epidemiological patterns of Argentine haemorrhagic fever. JI Maiztegui, Bull World Health Organ 1975 52 567 575 1085212
7. A prospective study of the epidemiology and ecology of Lassa fever. JB McCormick PA Webb JW Krebs KM Johnson ES Smith, J Infect Dis 1987 155 437 444 3805771
8. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. JI Maiztegui KT McKee Jr JG Barrera Oro LH Harrison PH Gibbs MR Feuillade DA Enria AM Briggiler SC Levis AM Ambrosio NA Halsey CJ Peters, J Infect Dis 1998 177 277 283 10.1086/514211 9466512
9. Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever. DA Enria AM Briggiler S Levis D Vallejos JI Maiztegui PG Canonico, Antiviral Res 1987 7 353 359 10.1016/0166-3542(87)90017-9 2445283
10. Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. KT McKee Jr JW Huggins CJ Trahan BG Mahlandt, Antimicrob Agents Chemother 1988 32 1304 1309 2848441
11. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Botten J Alexander V Pasquetto J Sidney P Barrowman J Ting B Peters S Southwood B Stewart MP Rodriguez-Carreno B Mothe JL Whitton A Sette MJ Buchmeier, J Virol 2006 80 8351 8361 10.1128/JVI.00896-06 16912286
12. HLA-A2-Restricted Protection against Lethal Lymphocytic Choriomeningitis. J Botten JL Whitton P Barrowman J Sidney JK Whitmire J Alexander JP Ting HH Bui A Sette MJ Buchmeier, J Virol 2007 81 2307 2317 10.1128/JVI.02063-06 17166907
13. The CD8+ T-cell response to lymphocytic choriomeningitis virus involves the L antigen: uncovering new tricks for an old virus. MF Kotturi B Peters F Buendia-Laysa Jr J Sidney C Oseroff J Botten H Grey MJ Buchmeier A Sette, J Virol 2007 81 4928 4940 10.1128/JVI.02632-06 17329346
14. A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. MF Kotturi J Botten J Sidney HH Bui L Giancola M Maybeno J Babin C Oseroff V Pasquetto JA Greenbaum B Peters J Ting D Do L Vang J Alexander H Grey MJ Buchmeier A Sette, PLoS Pathog 2009 5 1000695 10.1371/journal.ppat.1000695 20019801
15. Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. DD Auperin JJ Esposito JV Lange SP Bauer J Knight DR Sasso JB McCormick, Virus Res 1988 9 233 248 10.1016/0168-1702(88)90033-0 3354260
16. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. HG Morrison SP Bauer JV Lange JJ Esposito JB McCormick DD Auperin, Virology 1989 171 179 188 10.1016/0042-6822(89)90525-4 2741340
17. Effective vaccine for lassa fever. SP Fisher-Hoch L Hutwagner B Brown JB McCormick, J Virol 2000 74 6777 6783 10.1128/JVI.74.15.6777-6783.2000 10888616
18. Current progress towards vaccines for arenavirus-caused diseases. JC Clegg, Vaccine 1992 10 89 95 10.1016/0264-410X(92)90022-C 1311492
19. Towards a human Lassa fever vaccine. SP Fisher-Hoch JB McCormick, Rev Med Virol 2001 11 331 341 10.1002/rmv.329 11590670
20. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. JB McCormick, Med Microbiol Immunol 1986 175 153 155 10.1007/BF02122438 3724661
21. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. JI Maiztegui NJ Fernandez AJ de Damilano, Lancet 1979 2 1216 1217 10.1016/S0140-6736(79) 92335-3 92624
22. Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. KT McKee Jr JG Oro AI Kuehne JA Spisso BG Mahlandt, Am J Trop Med Hyg 1993 48 403 411 8385886
23. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. EM Janssen EE Lemmens T Wolfe U Christen MG von Herrath SP Schoenberger, Nature 2003 421 852 856 10.1038/nature01441 12594515
24. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. M Battegay D Moskophidis A Rahemtulla H Hengartner TW Mak RM Zinkernagel, J Virol 1994 68 4700 4704 7911534
25. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. M Matloubian RJ Concepcion R Ahmed, J Virol 1994 68 8056 8063 7966595
26. IL-21 is required to control chronic viral infection. H Elsaesser K Sauer DG Brooks, Science 2009 324 1569 1572 10.1126/science.1174182 19423777
27. A vital role for interleukin-21 in the control of a chronic viral infection. JS Yi M Du AJ Zajac, Science 2009 324 1572 1576 10.1126/science. 1175194 19443735
28. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. A Frohlich J Kisielow I Schmitz S Freigang AT Shamshiev J Weber BJ Marsland A Oxenius M Kopf, Science 2009 324 1576 1580 10.1126/science.1172815 19478140
29. Cutting edge: MHC class II-restricted killing in vivo during viral infection. ER Jellison SK Kim RM Welsh, J Immunol 2005 174 614 618 15634878
30. Several common HLA-DR types share largely overlapping peptide binding repertoires. S Southwood J Sidney A Kondo MF del Guercio E Appella S Hoffman RT Kubo RW Chesnut HM Grey A Sette, J Immunol 1998 160 3363 3373 9531296
31. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. JM Calvo-Calle I Strug MD Nastke SP Baker LJ Stern, PLoS Pathog 2007 3 1511 1529 10.1371/journal.ppat.0030144 17937498
32. The T cell response of HLA-DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. DM Altmann DC Douek AJ Frater CM Hetherington H Inoko JI Elliott, J Exp Med 1995 181 867 875 10.1084/jem.181.3.867 7532684
33. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. PA Darrah DT Patel PM de Luca RW Lindsay DF Davey BJ Flynn ST Hoff P Andersen SG Reed SL Morris M Roederer RA Seder, Nat Med 2007 13 843 850 10.1038/nm1592 17558415
34. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. D Ciuffreda D Comte M Cavassini E Giostra L Buhler M Perruchoud MH Heim M Battegay D Genne B Mulhaupt R Malinverni C Oneta E Bernasconi M Monnat A Cerny C Chuard J Borovicka G Mentha M Pascual JJ Gonvers G Pantaleo V Dutoit, Eur J Immunol 2008 38 2665 2677 10.1002/eji.200838336 18958874
35. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. SR Bennett FR Carbone F Karamalis RA Flavell JF Miller WR Heath, Nature 1998 393 478 480 10.1038/30996 9624004
36. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. JP Ridge F Di Rosa P Matzinger, Nature 1998 393 474 478 10.1038/30989 9624003
37. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. SP Schoenberger RE Toes EI van der Voort R Offringa CJ Melief, Nature 1998 393 480 483 10.1038/31002 9624005
38. Molecular mechanism and function of CD40/CD40L engagement in the immune system. R Elgueta MJ Benson VC de Vries A Wasiuk Y Guo RJ Noelle, Immunol Rev 2009 229 152 172 10.1111/j.1600-065X.2009.00782.x 19426221
39. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. HH Bui J Sidney K Dinh S Southwood MJ Newman A Sette, BMC Bioinformatics 2006 7 153 10.1186/1471-2105-7-153 16545123
40. Single Locus Polymorphism of Classical HLA Genes. D Meyer RM Singe SJ Mack A Lancaster MP Nelson H Erlich M Frenandez-Vina G Thomson, Immunobiology of the Human MHC: Proceedings of the 13th International Histocompatibility Workshop and Conference; Seattle, WA IHWG Press, Hansen JA, 2007 653 704
41. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J ter Meulen M Badusche K Kuhnt A Doetze J Satoguina T Marti C Loeliger K Koulemou L Koivogui H Schmitz B Fleischer A Hoerauf, J Virol 2000 74 2186 2192 10.1128/JVI.74.5.2186-2192.2000 10666248
42. Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. J Meulen M Badusche J Satoguina T Strecker O Lenz C Loeliger M Sakho K Koulemou L Koivogui A Hoerauf, Virology 2004 321 134 143 10.1016/j.virol.2003.12.013 15033572
43. Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. A Geluk V Taneja KE van Meijgaarden E Zanelli C Abou-Zeid JE Thole RR de Vries CS David TH Ottenhoff, Proc Natl Acad Sci USA 1998 95 10797 10802 10.1073/pnas.95.18.10797 9724784
44. HLA class II transgenic mice mimic human inflammatory diseases. AK Mangalam G Rajagopalan V Taneja CS David, Adv Immunol 2008 97 65 147
45. Pneumococcal vaccines: an update on current strategies. D Bogaert PW Hermans PV Adrian HC Rumke R de Groot, Vaccine 2004 22 2209 2220 10.1016/j.vaccine.2003.11.038 15149779
46. Developing an HPV vaccine to prevent cervical cancer and genital warts. JT Bryan, Vaccine 2007 25 3001 3006 10.1016/j.vaccine.2007.01.013 17289220
47. Adaptive immunity to Lymphocyctic choriomeningitis virus: new insights into antigenic determinants. JW Botten MF Kotturi, Future Virology 2007 2 495 508 10.2217/17460794.2.5.495 (Pubitemid 47455749)
48. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. D Homann H Lewicki D Brooks J Eberlein V Mallet-Designe L Teyton MB Oldstone, Virology 2007 363 113 123 10.1016/j.virol.2006.12.025 17320138
49. Chronic lymphocytic choriomeningitis virus infection actively down-regulates CD4+ T cell responses directed against a broad range of epitopes. BR Mothe BS Stewart C Oseroff HH Bui S Stogiera Z Garcia C Dow MP Rodriguez-Carreno M Kotturi V Pasquetto J Botten S Crotty E Janssen MJ Buchmeier A Sette, J Immunol 2007 179 1058 1067 17617598
50. Lymphocytic choriomeningitis virus infection yields overlapping CD4+ and CD8+ T-cell responses. C Dow C Oseroff B Peters C Nance-Sotelo J Sidney M Buchmeier A Sette BR Mothe, J Virol 2008 82 11734 11741 10.1128/JVI.00435-08 18829752
51. Uneven distribution of MHC class II epitopes within the influenza virus. SR Crowe SC Miller DM Brown PS Adams RW Dutton AG Harmsen FE Lund TD Randall SL Swain DL Woodland, Vaccine 2006 24 457 467 10.1016/j.vaccine.2005.07.096 16140434
52. Functional signatures of protective antiviral T-cell immunity in human virus infections. A Harari V Dutoit C Cellerai PA Bart RA Du Pasquier G Pantaleo, Immunol Rev 2006 211 236 254 10.1111/j.0105-2896.2006.00395.x 16824132
53. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. MR Betts MC Nason SM West SC de Rosa SA Migueles J Abraham MM Lederman JM Benito PA Goepfert M Connors M Roederer RA Koup, Blood 2006 107 4781 4789 10.1182/blood-2005-12-4818 16467198
54. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. JR Almeida DA Price L Papagno ZA Arkoub D Sauce E Bornstein TE Asher A Samri A Schnuriger I Theodorou D Costagliola C Rouzioux H Agut AG Marcelin D Douek B Autran V Appay, J Exp Med 2007 204 2473 2485 10.1084/jem.20070784 17893201
55. Polyfunctional T cell responses are a hallmark of HIV-2 infection. MG Duvall ML Precopio DA Ambrozak A Jaye AJ McMichael HC Whittle M Roederer SL Rowland-Jones RA Koup, Eur J Immunol 2008 38 350 363 10.1002/eji.200737768 18200635
56. Measurement of MHC/peptide interactions by gel filtration. J Sidney S Southwood C Oseroff MFD Guercio A Sette H Grey, Current Protocols in Immunology I New York: John Wiley & Sons, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, 1998 18.13.11 18.13.19
57. Biodefense and Emerging Infections Research Resources Repository. http://www.beiresources.org
58. Vaccinia virus-specific CD4+ T cell responses target a set of antigens largely distinct from those targeted by CD8+ T cell responses. M Moutaftsi HH Bui B Peters J Sidney S Salek-Ardakani C Oseroff V Pasquetto S Crotty M Croft EJ Lefkowitz H Grey A Sette, J Immunol 2007 178 6814 6820 17513729